Loading, please wait....jpg)
.jpg)
CONTINUING PHARMACY EDUCATION
Buprenorphine in the Management of Opioid Use Disorder (OUD):
Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies
Speaker: Michael Biglow, PharmD, BCPS, BCPP, Clinical Manager, Inpatient Pharmacy Services, Presbyterian Healthcare Services, Albuquerque, NM
ACPE Universal Program ID# 0122-0000-25-046-H08-P/T (Application-Based CE)
1 Contact Hours [0.1 CEU]
Release Date: August 11, 2025
Expiration Date: August 11, 2028
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Application
Target Audience(s)
- Pharmacists and Pharmacy Technicians
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
There are 2 steps to completing this home-study CE.
Step 1: Watch the video presentation in its entirety.
Step 2: Click on "Take the Test" to complete the post-test and evaluation.
Please Note: A handout is provided. Please print it out and follow along with the audio recording.
Objectives
- Review the unique properties and advantages of buprenorphine in the management of OUD
- Analyze novel dosing strategies for induction of high-risk patients
- Discuss the potential impact of the MAT Act (i.e. removal of the DATA 200 waiver) on patient access to buprenorphine
- Evaluate patient-specific parameters when considering long-acting injectable formulations
- Develop management strategies for use of buprenorphine in special populations (e.g. pediatrics, obstetrics)
Speaker(s)/Author(s)
|
Michael Biglow, PharmD, BCPS, BCPP
|
Activity Number
0122-0000-25-046-H08-P/T
Release Date:
Aug 11, 2025
Credit Expiration Date:
Aug 11, 2028
CE Hours
1.00